• News
  • Publications
  • Videos
  • Events
  • About
  • Contact

Patient-Derived Organoids Show Promise for Personalized Therapy in Pancreatic Cancer

May 6, 2020

Manuel Hidalgo Medina, MD, PhD Patient-derived organoids (PDOs) may possess the potential to personalize therapy and allow for the exclusion of ineffective drugs from combination regimens, reducing toxicity in patients with pancreatic cancer, according to preliminary results from the HOPE trial. 1 As such, it is anticipated that this […]

View Original Source at Patient-Derived Organoids Show Promise for Personalized Therapy in Pancreatic Cancer

Weekly Digest

Sign up to receive
weekly updates!

    No Spum Guarantee

    Cancer Types

    • Bladder Cancer Research (2)
    • Bowel Cancer Research (3)
    • Brain Cancer Research (7)
    • Breast cancer (6)
    • cervical cancer (1)
    • colon (1)
    • Colon cancer (14)
    • colorectal cancer (6)
    • Drug development (12)
    • Endometrial cancer (2)
    • Esophageal cancer (3)
    • Gastric cancer (5)
    • Hans Clevers (1)
    • Head and neck cancer (4)
    • Immunotherapy (0)
    • Intestinal cancer (8)
    • intestinal organoids (1)
    • Kidney cancer (3)
    • Leukemia (1)
    • Liver cancer (11)
    • Lung cancer (4)
    • melanoma (1)
    • metastatic cancer (1)
    • Organoid (143)
    • Ovarian cancer (8)
    • Pancreatic cancer (19)
    • Peritoneal cancer (1)
    • Personalized medicine (5)
    • Prostate cancer (7)
    • Rectal cancer (1)
    • solid tumor (1)
    • stem cells (1)

    ORG
    1-617-547-9443

    Monday-Friday: 8 am - 8 pm
    Saturday: 8 am - 4:30 pm

    • News
    • Publications
    • Videos
    • Events
    • About Us
    • Contact Us
    • Privacy
    • Terms of Use

    © COPYRIGHT 2022 Organoid Research Group. ALL RIGHTS RESERVED.